Neuromuscular Blocking Agent (NMBA) Market by Type and Application - Global Industry Analysis & Forecast to 2027

Published On : January 2020 Pages : 170 Category: Pharma & Healthcare Report Code : HC018618

Neuromuscular Blocking Agent (NMBA) Market By Type (Depolarizing, Non-depolarizing) and Application (Hospital, Pharmacy, Clinic, Others) - Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

The Neuromuscular Blocking Agent (NMBA) Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Neuromuscular Blocking Agent (NMBA) market is anticipated to accrue substantial returns by the end of the forecast period, while depicting a modest CAGR over the projected duration.

Drivers and Restraints

Top-down and bottom-up approaches are used to validate the global Neuromuscular Blocking Agent (NMBA) Market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Regional Insights

The data for 2019 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis                         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • AbbVie
  • GlaxoSmithKline
  • Pfizer
  • Hengrui Pharmaceutical
  • Abbott Laboratories
  • Fresenius Kabi
  • Sandoz
  • Somerset Therapeutics
  • Guike Pharmaceutical

Some of the key questions answered by the report are:

  • What was the market size in 2014 and forecast from 2020 to 2027?
  • What will be the industry market growth from 2016 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Neuromuscular Blocking Agent (NMBA) Market, By Type, Estimates and Forecast, 2016-2027 ($Million)

o    Depolarizing

o    Non-depolarizing

·         Neuromuscular Blocking Agent (NMBA) Market, By Application, Estimates and Forecast, 2016-2027 ($Million)

o    Hospital

o    Pharmacy

o    Clinic

o    Others

·         Neuromuscular Blocking Agent (NMBA) Market, By Key Players, Estimates and Forecast, 2016-2027 ($Million)

o    AbbVie

o    GlaxoSmithKline

o    Pfizer

o    Hengrui Pharmaceutical

o    Abbott Laboratories

o    Fresenius Kabi

o    Sandoz

o    Somerset Therapeutics

o    Guike Pharmaceutical

·         Neuromuscular Blocking Agent (NMBA) Market, By Region, Estimates and Forecast, 2016-2027 ($Million)

o    North America

§  North America Neuromuscular Blocking Agent (NMBA) Market, By Country

o    U.S. Neuromuscular Blocking Agent (NMBA) Market

o    Canada Neuromuscular Blocking Agent (NMBA) Market

o    Mexico Neuromuscular Blocking Agent (NMBA) Market

o    Europe

§  Europe Neuromuscular Blocking Agent (NMBA) Market, By Country

o    Germany Neuromuscular Blocking Agent (NMBA) Market

o    UK Neuromuscular Blocking Agent (NMBA) Market

o    France Neuromuscular Blocking Agent (NMBA) Market

o    Russia Neuromuscular Blocking Agent (NMBA) Market

o    Italy Neuromuscular Blocking Agent (NMBA) Market

o    Rest of Europe Neuromuscular Blocking Agent (NMBA) Market

o    Asia-Pacific

§  Asia-Pacific Neuromuscular Blocking Agent (NMBA) Market, By Country

o    China Neuromuscular Blocking Agent (NMBA) Market

o    Japan Neuromuscular Blocking Agent (NMBA) Market

o    South Korea Neuromuscular Blocking Agent (NMBA) Market

o    India Neuromuscular Blocking Agent (NMBA) Market

o    Southeast Asia Neuromuscular Blocking Agent (NMBA) Market

o    Rest of Asia-Pacific Neuromuscular Blocking Agent (NMBA) Market

o    South America

§  South America Neuromuscular Blocking Agent (NMBA) Market

o    Brazil Neuromuscular Blocking Agent (NMBA) Market

o    Argentina Neuromuscular Blocking Agent (NMBA) Market

o    Columbia Neuromuscular Blocking Agent (NMBA) Market

o    Rest of South America Neuromuscular Blocking Agent (NMBA) Market

o    Middle East and Africa

§  Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market

o    Saudi Arabia Neuromuscular Blocking Agent (NMBA) Market

o    UAE Neuromuscular Blocking Agent (NMBA) Market

o    Egypt Neuromuscular Blocking Agent (NMBA) Market

o    Nigeria Neuromuscular Blocking Agent (NMBA) Market

o    South Africa Neuromuscular Blocking Agent (NMBA) Market

o    Rest of MEA Neuromuscular Blocking Agent (NMBA) Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2016-2027)

4.1.2.  Canada Market Status and Outlook (2016-2027)

4.1.3.  Mexico Market Status and Outlook (2016-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2016-2027)

4.2.2.  France Market Status and Outlook (2016-2027)

4.2.3.  UK Market Status and Outlook (2016-2027)

4.2.4.  Russia Market Status and Outlook (2016-2027)

4.2.5.  Italy Market Status and Outlook (2016-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2016-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2016-2027)

4.3.2.  Japan Market Status and Outlook (2016-2027)

4.3.3.  Korea Market Status and Outlook (2016-2027)

4.3.4.  India Market Status and Outlook (2016-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2016-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2016-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2016-2027)

4.4.2.  Argentina Market Status and Outlook (2016-2027)

4.4.3.  Columbia Market Status and Outlook (2016-2027)

4.4.4.  Rest of South America Market Status and Outlook (2016-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2016-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2016-2027)

4.5.3.  Egypt Market Status and Outlook (2016-2027)

4.5.4.  Nigeria Market Status and Outlook (2016-2027)

4.5.5.  South Africa Market Status and Outlook (2016-2027)

4.5.6.  Turkey Market Status and Outlook (2016-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2016-2027)

5.       Neuromuscular Blocking Agent (NMBA) Market, By Type

5.1.     Introduction

5.2.     Global Neuromuscular Blocking Agent (NMBA) Revenue and Market Share by Type  (2016-2019)

5.2.1.  Global Neuromuscular Blocking Agent (NMBA) Revenue and Revenue Share by Type  (2016-2019)

5.3.     Depolarizing

5.3.1.  Global Depolarizing Revenue and Growth Rate (2016-2019)

5.4.     Non-depolarizing

5.4.1.  Global Non-depolarizing Revenue and Growth Rate (2016-2019)

6.       Neuromuscular Blocking Agent (NMBA) Market, By Application

6.1.     Introduction

6.2.     Global Neuromuscular Blocking Agent (NMBA) Revenue and Market Share by Application  (2016-2019)

6.2.1.  Global Neuromuscular Blocking Agent (NMBA) Revenue and Revenue Share by Application  (2016-2019)

6.3.     Hospital

6.3.1.  Global Hospital Revenue and Growth Rate (2016-2019)

6.4.     Pharmacy

6.4.1.  Global Pharmacy Revenue and Growth Rate (2016-2019)

6.5.     Clinic

6.5.1.  Global Clinic Revenue and Growth Rate (2016-2019)

6.6.     Others

6.6.1.  Global Others Revenue and Growth Rate (2016-2019)

7.       Neuromuscular Blocking Agent (NMBA) Market, By Region

7.1.     Introduction

7.2.     Global Neuromuscular Blocking Agent (NMBA) Revenue and Market Share by Regions

7.2.1.  Global Neuromuscular Blocking Agent (NMBA) Revenue by Regions (2016-2019)

7.3.     North America Neuromuscular Blocking Agent (NMBA) by Countries

7.3.1.  North America Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2019)

7.3.2.  North America Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) by Countries (2016-2019)

7.3.3.  United States

7.3.3.1.  United States Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.3.4.  Canada

7.3.4.1.  Canada Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.3.5.  Mexico

7.3.5.1.  Mexico Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.     Europe Neuromuscular Blocking Agent (NMBA) by Countries

7.4.1.  Europe Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2019)

7.4.2.  Europe Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) by Countries (2016-2019)

7.4.3.  Germany

7.4.3.1.  Germany Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.4.  France

7.4.4.1.  France Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.5.  UK

7.4.5.1.  UK Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.6.  Russia

7.4.6.1.  Russia Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.7.  Italy

7.4.7.1.  Italy Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.8.  Rest of Europe

7.4.8.1.  Rest of Europe Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.     Asia-Pacific Neuromuscular Blocking Agent (NMBA) by Countries

7.5.1.  Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2019)

7.5.2.  Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) by Countries (2016-2019)

7.5.3.  China

7.5.3.1.  China Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.4.  Japan

7.5.4.1.  Japan Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.5.  Korea

7.5.5.1.  Korea Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.6.  India

7.5.6.1.  India Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.7.  Southeast Asia

7.5.7.1.  Southeast Asia Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.8.  Rest of Asia-Pacific

7.5.8.1.  Rest of Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.6.     South America Neuromuscular Blocking Agent (NMBA) by Countries

7.6.1.  South America Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2019)

7.6.2.  South America Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) by Countries (2016-2019)

7.6.3.  Brazil

7.6.3.1.  Brazil Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.6.4.  Argentina

7.6.4.1.  Argentina Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.6.5.  Columbia

7.6.5.1.  Columbia Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.6.6.  Rest of South America

7.6.6.1.  Rest of South America Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.     Middle East and Africa Neuromuscular Blocking Agent (NMBA) by Countries

7.7.1.  Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2019)

7.7.2.  Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) by Countries (2016-2019)

7.7.3.  Saudi Arabia

7.7.3.1.  Saudi Arabia Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.4.  United Arab Emirates

7.7.4.1.  United Arab Emirates Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.5.  Egypt

7.7.5.1.  Egypt Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.6.  Nigeria

7.7.6.1.  Nigeria Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.7.  South Africa

7.7.7.1.  South Africa Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.8.  Turkey

7.7.8.1.  Turkey Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.9.  Rest of Middle East and Africa

7.7.9.1.  Rest of Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)

8.       Company Profiles

8.1.     AbbVie

8.1.1.  Business Overview

8.1.2.   Service Portfolio

8.1.3.  Strategic Developments

8.1.4.  Financial Overview

8.2.     GlaxoSmithKline

8.2.1.  Business Overview

8.2.2.   Service Portfolio

8.2.3.  Strategic Developments

8.2.4.  Financial Overview

8.3.     Pfizer

8.3.1.  Business Overview

8.3.2.   Service Portfolio

8.3.3.  Strategic Developments

8.3.4.  Financial Overview

8.4.     Hengrui Pharmaceutical

8.4.1.  Business Overview

8.4.2.   Service Portfolio

8.4.3.  Strategic Developments

8.4.4.  Financial Overview

8.5.     Abbott Laboratories

8.5.1.  Business Overview

8.5.2.   Service Portfolio

8.5.3.  Strategic Developments

8.5.4.  Financial Overview

8.6.     Fresenius Kabi

8.6.1.  Business Overview

8.6.2.   Service Portfolio

8.6.3.  Strategic Developments

8.6.4.  Financial Overview

8.7.     Sandoz

8.7.1.  Business Overview

8.7.2.   Service Portfolio

8.7.3.  Strategic Developments

8.7.4.  Financial Overview

8.8.     Somerset Therapeutics

8.8.1.  Business Overview

8.8.2.   Service Portfolio

8.8.3.  Strategic Developments

8.8.4.  Financial Overview

8.9.     Guike Pharmaceutical

8.9.1.  Business Overview

8.9.2.   Service Portfolio

8.9.3.  Strategic Developments

8.9.4.  Financial Overview

9.       Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.1.     Global Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2019-2027)

9.2.     Neuromuscular Blocking Agent (NMBA) Market Forecast by Regions (2019-2027)

9.2.1.  North America Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.1.1.  United States Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.1.2.  Canada Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.1.3.  Mexico Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.2.  Europe Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.2.1.  Germany Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.2.2.  France Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.2.3.  UK Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.2.4.  Russia Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.2.5.  Italy Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.2.6.  Rest of Europe Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.3.  Asia-Pacific Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.3.1.  China Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.3.2.  Japan Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.3.3.  Korea Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.3.4.  India Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.3.5.  Southeast Asia Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.3.6.  Rest of Asia-Pacific Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.4.  South America Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.4.1.  Brazil Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.4.2.  Argentina Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.4.3.  Columbia Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.4.4.  Rest of South America Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.5.  Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.5.1.  Saudi Arabia Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.5.2.  United Arab Emirates Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.5.3.  Egypt Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.5.4.  Nigeria Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.5.5.  South Africa Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.5.6.  Turkey Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.2.5.7.  Rest of Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)

9.3.     Neuromuscular Blocking Agent (NMBA) Market Forecast by Type  (2019-2027)

9.3.1.  Neuromuscular Blocking Agent (NMBA) Forecast by Type  (2019-2027)

9.3.2.  Neuromuscular Blocking Agent (NMBA) Market Share Forecast by Type  (2019-2027)

9.4.     Neuromuscular Blocking Agent (NMBA) Market Forecast by Application  (2019-2027)

9.4.1.  Neuromuscular Blocking Agent (NMBA) Forecast by Application  (2019-2027)

9.4.2.  Neuromuscular Blocking Agent (NMBA) Market Share Forecast by Application  (2019-2027)


List of Tables

List of Tables and Figures:

Figure United States Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Canada Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Mexico Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Germany Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure France Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure UK Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Russia Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Italy Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Rest of Europe Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure China Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Japan Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Korea Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure India Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Southeast Asia Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Rest of Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Brazil Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Argentina Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Columbia Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Rest of South America Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Saudi Arabia Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure United Arab Emirates Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Egypt Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Nigeria Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure South Africa Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Turkey Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Figure Rest of Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) and Growth Rate (2016-2027)
Table Global Neuromuscular Blocking Agent (NMBA) Revenue and Revenue Share by Type (2016-2019)
Figure Global Depolarizing Revenue and Growth Rate (2016-2019)
Figure Global Non-depolarizing Revenue and Growth Rate (2016-2019)
Table Global Neuromuscular Blocking Agent (NMBA) Revenue and Revenue Share by Application (2016-2019)
Figure Global Hospital Revenue and Growth Rate (2016-2019)
Figure Global Pharmacy Revenue and Growth Rate (2016-2019)
Figure Global Clinic Revenue and Growth Rate (2016-2019)
Figure Global Others Revenue and Growth Rate (2016-2019)
Table Global Neuromuscular Blocking Agent (NMBA) Revenue by Regions (2016-2019)
Figure North America Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure North America Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2019)
Figure North America Neuromuscular Blocking Agent (NMBA) by Countries (2016-2019)
Figure North America Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) by Countries (2016-2019)
Figure United States Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure United States Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Canada Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Canada Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Mexico Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Mexico Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Europe Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Europe Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2019)
Figure Europe Neuromuscular Blocking Agent (NMBA) by Countries (2016-2019)
Figure Europe Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) by Countries (2016-2019)
Figure Germany Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Germany Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure France Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure France Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure UK Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure UK Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Russia Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Russia Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Italy Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Italy Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Rest of Europe Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Rest of Europe Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Asia-Pacific Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2019)
Figure Asia-Pacific Neuromuscular Blocking Agent (NMBA) by Countries (2016-2019)
Figure Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) by Countries (2016-2019)
Figure China Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure China Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Japan Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Japan Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Korea Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Korea Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure India Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure India Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Southeast Asia Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Southeast Asia Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Rest of Asia-Pacific Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Rest of Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure South America Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure South America Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2019)
Figure South America Neuromuscular Blocking Agent (NMBA) by Countries (2016-2019)
Figure South America Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) by Countries (2016-2019)
Figure Brazil Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Brazil Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Argentina Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Argentina Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Columbia Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Columbia Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Rest of South America Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Rest of South America Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Middle East and Africa Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2019)
Figure Middle East and Africa Neuromuscular Blocking Agent (NMBA) by Countries (2016-2019)
Figure Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue (Million USD) by Countries (2016-2019)
Figure Saudi Arabia Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Saudi Arabia Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure United Arab Emirates Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure United Arab Emirates Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Egypt Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Egypt Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Nigeria Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Nigeria Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure South Africa Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure South Africa Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Turkey Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Turkey Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Rest of Middle East and Africa Neuromuscular Blocking Agent (NMBA) Growth Rate (2016-2019)
Figure Rest of Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2016-2019)
Table AbbVie Neuromuscular Blocking Agent (NMBA) Financial Overview
Table GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Financial Overview
Table Pfizer Neuromuscular Blocking Agent (NMBA) Financial Overview
Table Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Financial Overview
Table Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Financial Overview
Table Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Financial Overview
Table Sandoz Neuromuscular Blocking Agent (NMBA) Financial Overview
Table Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Financial Overview
Table Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Financial Overview
Figure Global Neuromuscular Blocking Agent (NMBA) Revenue (Millions USD) and Growth Rate (2019-2027)
Table Neuromuscular Blocking Agent (NMBA) Market Forecast by Regions (2019-2027)
Figure North America Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure United States Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Canada Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Mexico Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Europe Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Germany Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure France Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure UK Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Russia Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Italy Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Rest of Europe Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Asia-Pacific Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure China Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Japan Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Korea Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure India Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Southeast Asia Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure South America Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Brazil Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Argentina Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Columbia Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Rest of South America Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Saudi Arabia Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure United Arab Emirates Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Egypt Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Nigeria Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure South Africa Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Turkey Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2027)
Figure Global Neuromuscular Blocking Agent (NMBA) Forecast by Type (2019-2027)
Figure Global Neuromuscular Blocking Agent (NMBA) Market Share Forecast by Type (2019-2027)
Figure Global Neuromuscular Blocking Agent (NMBA) Forecast by Type (2019-2027)
Figure Global Neuromuscular Blocking Agent (NMBA) Forecast by Application (2019-2027)
Figure Global Neuromuscular Blocking Agent (NMBA) Market Share Forecast by Application (2019-2027)
Figure Global Neuromuscular Blocking Agent (NMBA) Forecast by Application (2019-2027)

Please Note: Data related to the Companies are subject to Availability.


Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*